MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

ADMA Biologics Company Profile (NASDAQ:ADMA)

Consensus Ratings for ADMA Biologics (NASDAQ:ADMA) (?)
Ratings Breakdown: 1 Buy Rating(s), 1 Strong Buy Rating(s)
Consensus Rating:Strong Buy (Score: 3.50)
Consensus Price Target: $19.50 (319.35% upside)

Analysts' Ratings History for ADMA Biologics (NASDAQ:ADMA)
Show:
DateFirmActionRatingPrice TargetActions
9/17/2015Maxim GroupReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/9/2015Raymond JamesInitiated CoverageStrong-Buy$15.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/12/2015Maxim GroupReiterated RatingBuy$24.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/2/2015Maxim GroupReiterated RatingBuy$24.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/30/2015Maxim GroupReiterated RatingBuy$24.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/13/2015Maxim GroupBoost Price TargetBuy$18.00 -> $24.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/13/2015Maxim GroupSet Price TargetBuy$18.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/23/2015Maxim GroupSet Price TargetBuy$18.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/8/2014OppenheimerInitiated CoverageOutperform$20.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/1/2014Maxim GroupBoost Price TargetBuy$16.00 -> $18.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/11/2014Maxim GroupReiterated RatingPositive -> Buy$15.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 2/11/2014 forward)
            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by the American Association of Individual Investors As Featured by Seeking Alpha